Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Subscribe To Our Newsletter & Stay Updated
